Essential Pharma is a globally focused specialty pharmaceuticals business.

Essential Pharma is dedicated to maintaining access to clinically differentiated, niche, branded medicines across multiple therapeutic areas. The group has been an important and valued partner to healthcare providers for over 20 years by giving underserved patient populations access to medicines that otherwise might not be available, and addressing clinical unmet needs. Essential Pharma operates globally in more than 70 countries, supplying a portfolio of products with a focus on the central nervous system (CNS), gastroenterology, ophthalmology, and rare disease.

In 2019, Gyrus Capital, a Switzerland based PE group, acquired Essential Pharma from the founder to transition the business to institutional ownership.  Since the investment, Gyrus has repositioned the business from a UK-focused generics family business to a global provider of innovative and established medicines, through the execution of a focused M&A strategy and the creation of a Rare Disease platform.

In March 2025, Penta invested as part of a second close, into the Continuation Vehicle.